MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564603 | Name: CDK8/19-IN-51

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CDK8/19-IN-51 is a potent and selective dual inhibitor of CDK8 and CDK19.

Chemical Structure

CDK8/19-IN-51
CAS#NONE

Theoretical Analysis

MedKoo Cat#: 564603

Name: CDK8/19-IN-51

CAS#: NONE

Chemical Formula: C23H22N6O2

Exact Mass: 414.1804

Molecular Weight: 414.47

Elemental Analysis: C, 66.65; H, 5.35; N, 20.28; O, 7.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
CDK8/19 IN-51; CDK8/19-IN51; CDK8/19 IN 51; CDK8/19-IN-51
IUPAC/Chemical Name
(5-Amino-8-(4-(1-methyl-1H-pyrazol-4-yl)phenyl)-1,6-naphthyridin-2-yl)(3-methoxyazetidin-1-yl)methanone
InChi Key
OJIQEAIHEGJBFE-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H22N6O2/c1-28-11-16(9-26-28)14-3-5-15(6-4-14)19-10-25-22(24)18-7-8-20(27-21(18)19)23(30)29-12-17(13-29)31-2/h3-11,17H,12-13H2,1-2H3,(H2,24,25)
SMILES Code
O=C(C1=NC2=C(C3=CC=C(C4=CN(C)N=C4)C=C3)C=NC(N)=C2C=C1)N5CC(OC)C5
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 414.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Nakamura A, Nakata D, Kakoi Y, Kunitomo M, Murai S, Ebara S, Hata A, Hara T. CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells. Oncotarget. 2018 Feb 6;9(17):13474-13487. doi: 10.18632/oncotarget.24414. eCollection 2018 Mar 2. PubMed PMID: 29568371; PubMed Central PMCID: PMC5862592. 2: Fujimoto J, Hirayama T, Hirata Y, Hikichi Y, Murai S, Hasegawa M, Hasegawa Y, Yonemori K, Hata A, Aoyama K, Cary DR. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential. Bioorg Med Chem. 2017 Jun 15;25(12):3018-3033. doi: 10.1016/j.bmc.2017.03.049. Epub 2017 Mar 30. PubMed PMID: 28392276. 3: Ono K, Banno H, Okaniwa M, Hirayama T, Iwamura N, Hikichi Y, Murai S, Hasegawa M, Hasegawa Y, Yonemori K, Hata A, Aoyama K, Cary DR. Design and synthesis of selective CDK8/19 dual inhibitors: Discovery of 4,5-dihydrothieno[3',4':3,4]benzo[1,2-d]isothiazole derivatives. Bioorg Med Chem. 2017 Apr 15;25(8):2336-2350. doi: 10.1016/j.bmc.2017.02.038. Epub 2017 Feb 22. PubMed PMID: 28302507.